Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
Objective: To better understand exenatide’s role in the treatment of type 2 diabetes, this analysis assessed its cost-effectiveness in comparison to an intermediate (NPH) and long-acting insulin (glargine). Exenatide is a recently approved medication for the treatment of type 2 diabetes for use in a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2006-09-01
|
| Series: | Pharmacy Practice |
| Subjects: | |
| Online Access: | http://www.pharmacypractice.org/vol04/03/129-133.htm |